SEC Form 5 · accession 0000899243-18-003896
Whitehawk Therapeutics, Inc. · WHWK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anupam Dalal
Director
Period of report
Dec 31, 2017
Accepted (ET)
Feb 14, 2018 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422142
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 22, 2017 | J | 7,882 | $0.00 | D | 0 | I | See footnote |
| Common Stock | Dec 22, 2017 | J | 2,269 | $0.00 | A | 2,269 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The 7,882 shares of Common Stock are owned by directly by TWHVP SPV, LLC ("TWHVP"). The general partner of TWHVP is Kearny Venture Associates II, LLC ("KVA II"). KVA II has the sole voting and investment control over the shares owned by TWHVP and the Managing Members of KVA II have sole voting and investment control over the shares controlled by KVA II. The Managing Members of KVA II are Caley Castelein, Anupam Dalal and Andrew Jensen. None of the Managing Members of KVA II have individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Pursuant to the Limited Liability Company Agreement KVA II made an in-kind distribution to the members on December 22, 2017. KVA II currently owns 0 shares of the Issuer.
- F2Pro rata distribution from Kearny Venture Associates II, LLC., of which the reporting person is a managing member.